Search - tctmd.com

Displaying 221 - 240 of 380

Sort: Relevancy | Date

News Daily News

Postoperative A-fib Not as Bad as Nonsurgical A-fib for Thromboembolism

Todd Neale

March 29, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

Presentation JIM 2018

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Presenter: Roxana Mehran

February 23, 2018

News Daily News

Meta-analysis Supports Benefits of Short-term DAPT Among Elderly Patients

Yael L. Maxwell

February 20, 2018

News Daily News

Could NOACs Have a Role for Secondary Prevention After STEMI?

Todd Neale

February 08, 2018

News Daily News

Women Have Higher Risk of Unplanned Readmission After PCI

Michael O'Riordan

January 12, 2018

News Daily News

Coronary Embolism in STEMI Is Rare but Warrants a Unique Approach

Caitlin E. Cox

January 11, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

Todd Neale

November 16, 2017

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2017

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

Optimizing the Acute and Chronic Use of Antiplatelet and Antithrombotic Agents (and Their Combination): 2017 Update

Presenter: Debabrata Mukherjee, E. Murat Tuzcu, Dimitrios Alexopoulos

November 01, 2017

Presentation TCT 2017

TCT 91: Antithrombotic Therapy Post Transcatheter Aortic Valve Replacement in Patients With No Indication for Anticoagulation

Presenter: Kurt Huber, Jamil Abdalla Saad, Dimitrios Alexopoulos, Antonio L. Bartorelli, Bjorn Redfors, Carlos E. Uribe

October 31, 2017

News Daily News

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Yael L. Maxwell

October 23, 2017

News Daily News

Blood in Urine Carries Consequences for Patients on Antithrombotics

Yael L. Maxwell

October 09, 2017

Presentation

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

October 09, 2017

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

Advertisement

Postoperative A-fib Not as Bad as Nonsurgical A-fib for Thromboembolism

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Meta-analysis Supports Benefits of Short-term DAPT Among Elderly Patients

Could NOACs Have a Role for Secondary Prevention After STEMI?

Women Have Higher Risk of Unplanned Readmission After PCI

Coronary Embolism in STEMI Is Rare but Warrants a Unique Approach

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

RE-DUAL PCI Findings Consistent Across Key Subgroups

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Optimizing the Acute and Chronic Use of Antiplatelet and Antithrombotic Agents (and Their Combination): 2017 Update

TCT 91: Antithrombotic Therapy Post Transcatheter Aortic Valve Replacement in Patients With No Indication for Anticoagulation

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Blood in Urine Carries Consequences for Patients on Antithrombotics

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content